Evidence map›Paper›PMID 35909329›Full record

Trial reportActa obstetricia et gynecologica Scandinavica2022

Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial.

Annina H Haverinen, Kaisu M Luiro, Timea Szanto, Marika H Kangasniemi, Leena Hiltunen, Susanna Sainio, Terhi T Piltonen, Riitta Lassila, Juha S Tapanainen, Oskari Heikinheimo

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Acta obstetricia et gynecologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02352090 (Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02352090 phase4completednot on this map

Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.

TypeinterventionalSponsorHelsinki University Central HospitalRan2015 to 2018Enrolled59ConditionsContraceptionArmsEthinyl estradiol / dienogest, Estradiol valerate / dienogest, Dienogest
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Annina H HaverinenDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-5213-9747
Kaisu M LuiroDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Timea SzantoDepartment of Hematology and Comprehensive Cancer Center, Unit of Coagulation Disorders, Helsinki University Hospital, Helsinki, Finland.
Marika H KangasniemiDepartment of Obstetrics and Gynecology, University of Oulu, Oulu University Hospital and Medical Research Center PEDEGO Research Unit, Oulu, Finland.ORCID 0000-0003-0514-5981
Leena HiltunenDepartment of Hemostasis, Finnish Red Cross Blood Service, Helsinki, Finland.
Susanna SainioDepartment of Hemostasis, Finnish Red Cross Blood Service, Helsinki, Finland.ORCID 0000-0002-8908-8605
Terhi T PiltonenDepartment of Obstetrics and Gynecology, University of Oulu, Oulu University Hospital and Medical Research Center PEDEGO Research Unit, Oulu, Finland.
Riitta LassilaDepartment of Hematology and Comprehensive Cancer Center, Unit of Coagulation Disorders, Helsinki University Hospital, Helsinki, Finland.
Juha S TapanainenDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Oskari HeikinheimoDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-8671-130X
University of Helsinki · FIFinnish Red Cross · FIOulu University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionContraceptives containing ethinylestradiol (EE) induce changes in the coagulation system and are associated with a risk of venous thromboembolism. However, studies comparing the effects of combined oral contraceptives containing EE and low-potency estrogens (ie, estradiol [E MATERIAL AND

methodsWe enrolled 59 healthy, 18- to 35-year-old, non-smoking women, of whom three discontinued. The participants were randomly allocated to 9 weeks of continuous treatment with EV 2 mg + DNG 2-3 mg (n = 20), EE 0.03 mg + DNG 2 mg (n = 20), or DNG 2 mg (n = 19). Blood samples were collected at baseline and after 9 weeks. We assessed coagulation in vitro by thrombin generation using the Calibrated Automated Thrombogram. Thrombin generation was evaluated by lag time, time to thrombin peak, thrombin peak, and endogenous thrombin potential in response to tissue factor (1 pm). In vivo coagulation assessment was based on levels of prothrombin fragment 1 + 2 (F1 + 2) (thrombin generation) and D-dimer (fibrin turnover). CLINICAL

trial registrationNCT02352090.

resultsLag time and time to thrombin peak remained unaltered after exposure to EV + DNG, whereas EE + DNG shortened both lag time (mean percentage change -24%, 95% confidence interval [CI] -32% to -15%; p < 0.01) and time to thrombin peak (-26%, 95% CI -37% to -16%; p < 0.01). EV + DNG induced lower thrombin peak and endogenous thrombin potential than EE + DNG (peak; +45%, 95% CI 22%-67% vs +147%,95% CI 96%-198%; p < 0.01, and endogenous thrombin potential; +26%, 95% CI 15%-38% vs +64%, 95% CI 51%-76%; p < 0.01). Median F1 + 2 levels remained unchanged with EV + DNG (p = 0.22) but increased within normal ranges with EE + DNG (from 152 pmol/L, 95% CI 127-206] pmol/L to 194 pmol/L, 95% CI 149-250 pmol/L, p = 0.04). The within-group change in D-dimer levels was not significant in any of the groups. DNG alone did not affect these biomarkers.

conclusionsBoth in vitro and in vivo thrombin generation was lower after exposure to EV + DNG compared with EE + DNG. The lower thrombin generation measures after treatment with EV + DNG indicate less enhancement of coagulation potential and suggest that EV may be favorable to EE as a component of combined oral contraceptives.

Indexed as

Contraceptives, Oral, CombinedNandroloneAdolescentAdultEstradiolEstrogensEthinyl EstradiolFemaleFibrinHumansLevonorgestrelProgestinsThrombinThromboplastinYoung AdultContraceptives, Oral, CombinedEstradiolEstrogensEthinyl EstradiolFibrinLevonorgestrelNandroloneProgestinsThrombinThromboplastincoagulationcombined oral contraceptiondienogestestradiol valeratethrombin generation

Identifiers

PMID35909329
PMCPMC9812067
OpenAlexW4289174109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.